Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
We are pleased to attend the @AIESEC annual conference where we will share our positive partnership experience and discuss sustainability https://t.co/Z92f36PrNm https://t.co/mBNIHqhg62
— UCB News (@ucb_news) 11.02.2020 -
Although #EpilepsyDay has passed, UCB remains committed to improving epilepsy outcomes and has embarked on a global initiative to do just that. Find out more at https://t.co/FBAyoydUqG https://t.co/opdmZV5epQ
— UCB News (@ucb_news) 11.02.2020 -
‘Friendship & Inclusion’ is the theme of this years #EpilepsyDay but due to the stigma associated with epilepsy, patients still avoid seeking medical attention and some even resort to concealing their condition from their partner at the time of marria
— UCB News (@ucb_news) 10.02.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
